Ceftiofur (XNL) and its primary metabolite, desfuroylceftiofur (DXNL), were evaluated for in vitro activity against 53 9 isolates from veterinary sources. Actinobacillus pleuropneumoniae, Pasteurella spp., Haemophilus somnus, S almonella spp., Escherichia coli, staphylococci, and streptococci were tested. Overall, XNL and DXNL were equivalent in activity against the gram-negative organisms with all minimum inhibitory concentrations (MICs) within 1 serial dilution. Against the staphylococci, MIC differences of 2 -3 serial dilutions were detected with an MIC 90 for XNL and DXNL of 1 .0 and 4.0-8.0 g/ml, respectively. Although the MIC 90 obtained for S treptococcus suis for each compound was within 1 dilution, the MIC values against individual strains were 2 -3 dilutions greater for DXNL than for XNL. The MICs obtained with the bovine and equine streptococci for DXNL (MIC 90 = 0.03 g/ml) were 5 serial dilutions higher than those obtained for XNL (MIC 90 £ 0.001 9). Although DXNL was less active than XNL against the streptococci, these differences were not clinically important because both XNL and DXNL were highly active for these bacteria. Although these differences are of little importance with the streptococci, they may have important implications for susceptibility testing of the staphylococci. In conclusion, with the exception of the staphylococci, both XNL and DXNL were highly active against the organisms tested, with MICs for both compounds several fold lower than plasma levels achieved during dosing of XNL.
Metabolism of cephalosporins has been a concern with this class of antimicrobial agents since the initial release of cephalothin. 1 4,1 8 Cephalosporins with a 3 -acetoxy methyl substituent are rapidly modified by enzymes, both circulating and organ based, into less active deacetylated forms. 5,1 1 ,1 2 These deacetylated forms have been shown to be 4-1 6-fold less active than their parent compounds. 1 2-1 4,1 7 1 9 Although they are rapidly metabolized into less active metabolites, cephalosporins remain the most used antibacterial class of therapeutic agents. 1 0 Ceftiofur (XNL), a broad spectrum cephalosporin, was initially developed for the treatment of bovine respiratory disease (B RD) . 20 Recently, XNL was also approved for use in horses, swine, and poultry. Metabolism studies with XNL have shown that XNL is not present in the plasma of calves 1 hour after treatment with a 1 .0 mg/kg dose administered either intramuscularly o r intraveno usly. 2 Desfuro ylceftio fur (DXNL) is the most prevalent metabolite of XNL found in plasma. 2, 8 In cattle, this metabolite is formed when the thioesther bond of XNL is cleaved, probably by circulating enzymes, to form DXNL (Fig. 1 ) . 2, 7 Similar From Animal Health Discovery Research, Pharmacia & Upjohn Inc., 7000 Portage Road, Kalamazoo, MI 49001 . Current address (Y ancey): Central Research Division, Pfizer, 601 West Cornhusker Highway, PO B ox 80809, Lincoln, Received for publication June 5, 1 995. metabolic profiles have been shown for other animal species as we1 1 . 2, 8 To determine whether in vitro testing using XNL is predictive of activity of DXNL, studies comparing minimum inhibitory concentrations (MICs) of XNL and DXNL were necessary. Previous studies 3 have demonstrated comparable activity against streptococci and gram-negative bacilli; however, DXNL was less active than XNL when tested against staphylococci. These studies 3 tested a limited number of bacterial strains at dilutions commonly accepted for the testing of extended-spectrum cephalosporins. 1 Differences in activity were not detected because end point MICs were not achieved for most strains. The purpose of the present study was to compare the activities of XNL and DXNL against a large number of veterinary bacterial pathogens at dilutions well below those normally tested. Isolates were maintained at -70 C on 3 -mm sterile glass beads in trypticase soy broth a with 1 0% glycerol. Isolates were transferred onto freshly prepared trypticase soy agar a supplemented with 5% sheep blood or chocolate agar plates supplemented with 2% supplement C b (A. pleuropneumoniae) and incubated for 2 4 hr at 3 7 C in 5% CO 2 prior to testing.
Materials and methods
Antibiotics. Ceftiofur sodium and DXNL were produced by The Upjohn Company. These compounds were dissolved in 1 0% ethanol (v/v) in sterile distilled water. Dilutions for agar dilution MIC testing were prepared using sterile distilled water. Dilutions for microdilution MIC testing were prepared using the growth medium.
MICs. Equine streptococcal isolates and H. somnus were tested using the NCCLS agar dilution method 1 5 with Mueller-Hinton agar a supplemented with 5% sheep blood as the growth medium. The dilution range used for agar dilution testing was £ 0.001 9-4.0 g/ml. The remaining isolates were tested using the NCCLS microdilution method. 1 5 Mueller-Hinton broth was used as the growth medium for all of the isolates except A. pleuropneumoniae, for which Haemophilus test medium d was used. The dilution range for microdilution testing was 1 0.003 9-4.0 g/ml. B ecause of the instability of DXNL, especially as an aqueous solution, which promotes thiolactone formation, all agar dilution plates and microdilution panels containing this compound were prepared and S ummaries of MICs obtained with all isolates are provided in Tables 1 and 2 . All of the MIC values obtained with the quality control organisms were within expected ranges for XNL; 1 6 ranges are not available for DXNL. Individual MIC values obtained for both compounds against the gram-negative organisms were equal, within the limitations of the assay (Table 1 ) . The MIC 90 values were also within 1 dilution for XNL and DXNL against gram-negative organisms from bovine sources: P. multocida (£ 0.003 9 g/ml for XNL, 0.0078 g/ml for DXNL), P. haemolytica (0.01 5 g/ ml for XNL and DXNL), and S almonella spp. (1 .0 g/ ml for XNL, 2 .0 g/ml for DXNL); against organisms associated with S RD: P. multocida (£ 0.003 9 g/ml for XNL, 0.0078 g/ml for DXNL), A. pleuropneumo niae (0.0078 g /ml for XNL, 0.01 5 g /ml for DXNL); and S almonella choleraesuis (1 .0 g/ml for XNL and DXNL); and against the poultry E. coli isolates (0.5 g/ml for XNL and DXNL). Differences in MICs for isolates of H. somnus were not detected either, although all isolates yielded MICs £ 0.001 9 g/ ml for both compounds, the lowest dilution tested.
Unlike the gram-negative organisms, MICs obtained for DXNL against the staphylococci and streptococci were higher than those for XNL (Table 2 ) . Against the staphylococci, 2 -3 serial dilution increases were observed in MIC 90 values from XNL to DXNL (1 .0 g/ ml for XNL, 4.0-8.0 g/ml for DXNL). Up to 4 serial dilution differences were detected against isolates of S . uberis (0.03 g/ml for XNL, 0.5 g/ml for DXNL) and S . dysg alactiae (£0.003 9 for XNL, 0.03 for DXNL).
Against the equine streptococci, differences in MIC 90 dogs, DXNL is mostly protein bound. [6] [7] [8] In adult lacof > 5 serial dilutions were observed (£0.001 9 g/ml tating cows, DXNL is the major metabolite of XNL for XNL, 0.03 g/ml for DXNL). Although the MIC 90 in both plasma and milk, in which it is also protein values for XNL and DXNL were within 1 serial di-bound. 1 0 A similar metabolism scheme from XNL to lution against S . suis (0.1 3 g/ml for XNL, 0.2 5 g/ DXNL has been shown in other species as well (T. J. ml for DXNL), 2 -3 -fold dilution differences in MICs Gilbertson, 1 994, personal communication) . Further were observed among the individual isolates. studies have shown that in pigs, cattle, and horses, Discussion serum concentrations of DXNL are 1 0.2 g/ml for ‡ 2 4 hours after drug administration. 9 In the urine of S imilar to other cephalosporin antimicrobial agents adult cows, other metabolites found included DXNL possessing the 3 -acetoxy methyl substituent, including cysteine disulfide and 3 ,3 -desfuroylceftiofur disulfide. 7 cefotaxime, cephalothin, and cephapirin, XNL is rap-The biotransformation of DXNL to other metabolites idly metabolized in vivo into a desesterified form, can be reversible in vivo through thiol-disulfide inter-DXNL. 2 ,4,8,1 1 ,1 3,1 4 Metabolism studies have shown that change or the action of thiol reductases. 2 within 2 4 hours of dosing calves with XNL at 1 mg/ In vitro susceptibility testing plays an important role kg, > 95% of all the originally administered compound in predicting the efficacy of an antimicrobial agent is excreted, with 61 -77% of that dose being excreted against a bacterial pathogen. Often, the choice of anin the urine. 2 The majority of this excreted material timicrobial agent and its dosing is based on the outhas been shown to be DXNL, with only trace amounts come of the susceptibility test. B ecause DNXL is the of XNL being detected in rats and none in calves. 2,8 major metabolite of XNL, it was important to deter-These studies have also shown that XNL is not found mine whether in vitro susceptibility testing with XNL in detectable amounts in calf serum 1 hour after a dose is predictive of the activity of DXNL. This study of 1 mg/kg; rather, DXNL is found at levels of 3.75 showed that the MIC values obtained for gram-nega--0.44 g/ml at 1 hour after dosing. 2 DXNL is found tive organisms were the same for XNL and DXNL. free in serum in calves, but in adult cows, rats, and Against gram-positive organisms, however, DXNL was less active than XNL. Although DXNL was 2 -3 serial dilutions less active than XNL against the porcine and bovine streptococci and 5 serial dilutions less active against the equine streptococci, both compounds were highly active against all of the isolates tested. Differences in MIC values against the streptococci were only detected when isolates were tested at concentrations well below those recommended for testing of third generation cephalosporins. 1 These differences would likely be of little relevance in susceptibility predictions because the MIC 90 for DXNL against the streptococci is 7 serial dilutions lower than the plasma concentration of DXNL in horses, cattle, and swine. 2, 9 Differences were also detected with the bovine staphylococci tested. With the staphylococci, the MIC 90 values for XNL were 1 .0 g/ml, and the MIC 90 , values for DXNL ranged from 4.0 to 8.0 g/ml. Those isolates that had MICs of 8.0 g/ml for DXNL would yield a lower MIC when tested in vitro with XNL. These differences could be clinically important in the case of those staphylococci. However, because XNL is not indicated for use in treating staphylococcal infections of animals, this finding should not be of clinical importance.
Although the desesterified forms of cephalosporin agents are considerably less active than their parents, when tested in combination there was a synergistic interaction of the metabolites and cephalothin or cephapirin in 64% of isolates tested. 1 3 For cefotaxime, 75.8% of the strains tested showed either complete or partial synergy when tested in combination with desacetylcefotaxime. 1 2,1 7 In our study, XNL and DXNL were not tested in combination to determine synergy because XNL is rapidly and completely metabolized. 8 These results suggest that susceptibility testing with XNL is predictive of in vitro activity of XNL and its major metabolite, DXNL, for all pathogens of importance except the staphylococci. Both compounds were highly active against important pathogens associated with approved indications of XNL in cattle, horses, poultry, and swine. 
